Biomarkers play a vital role to inform treatment decision and revolutionize personalized medicine. According to the estimation of the Food and Drug Administration, 10% improvement in the ability to predict drug failures before clinical trials could save USD 100 million in development costs per drug. Another noteworthy application of circulating biomarkers testing is that it could be applied to every stage of cancer patient care. It can be used as an effective screening method for most of the patients as ctDNA is detected in most types of cancer at both early and advanced stages. Circulating biomarkers are an integral part of healthcare management due to its use in performing a biopsy, monitoring progression of disease, and effectiveness of a treatment regimen. Dying tumor cells release small pieces of their DNA into the bloodstream and these pieces are called cell-free circulating biomarkers. With the help of these biomarkers, patients’ prognosis is evaluated to improve drug development and identify patients who would receive maximum benefit from various treatment options. Pertaining to circulating biomarkers, broad array of specialties such as cancer, immunology, cardiovascular, neurology and metabolic disease for therapeutics and diagnosis are included. Furthermore, besides the potential role of circulating biomarkers as a detection and prognostic method, these biomarkers are also evaluated as a way of monitoring tumor progression and its response to a targeted drug treatment. A measurement of the amount of circulating biomarkers such as circulating tumor DNA (ctDNA) is extremely helpful to estimate a patient’s stage of cancer and survival chances.
Obtain the Forthcoming Trends for Circulating Biomarkers Market at:
The growth of healthcare industry and increasing investments in strengthening it have played a crucial role in the rising demand for circulating biomarkers. These biomarkers are extensively used for monitoring the progression of a disease, conducting a biopsy, and assessing the effectiveness of a treatment over a period of time. Biomarkers help in the accurate evaluation of patient’s prognosis, which is integral to adjusting or developing the treatment. Thus, circulating biomarkers are used for understanding the nature of immunology, cancer, neurology, cardiovascular, and metabolic disease. The Food and Drug Administration states that even a 10% advancement in understanding the positive or negative impact of drugs prior to clinical trials will result in savings worth US$100 mn of development expenditure for every drug.
In terms of regions, the global circulating biomarkers market is segmented into Asia Pacific, Europe, North America, and Rest of the World. Currently, North America leads the global market with Europe in tow. The high prevalence of cancer across North America is the primary reason for the high uptake of circulating biomarkers in the region. The America Cancer Society stated that cancer has become the second most popular reason for death. Presently, every one in four deaths in the United States is due to cancer. Analysts predict that Asia Pacific circulating biomarkers market will also register a rapid growth rate as the development of targeted therapies and personalized medicines are gaining a sizeable momentum.
Some of the key players in the global circulating biomarkers market are Affymetrix, Inc., Abbott Laboratories, Dickinson and Company, Becton, GE Healthcare, Agilent Technologies, Inc., Biocept, Inc., and Epigenomics AG. The research report offers an explanation of the competitive landscape present in the global market. It estimates the intensity of the competitive rivalry, business and marketing strategies, and research and development activities of these players. The report also documents the recent developments in the global circulating biomarkers market and analyzes their impact on the future of the overall market dynamics.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453